(TLND) |
| 0 (0%) 01-13 23:35 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 77.09 |
| Resistance 1: | 66.00 |
| Pivot price: | 65.92 |
| Support 1: | 65.32 |
| Support 2: | 64.90 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | -2.660 |
| Book Value | 0.200 |
| PEG Ratio | 0.00 |
| Gross Profit | 6.881 |
| Profit Margin (%) | -28.29 |
| Operating Margin (%) | -23.61 |
| Return on Assets (ttm) | -11.6 |
| Return on Equity (ttm) | -439.7 |
Company news
Tue, 30 Sep 2025
Neoadjuvant outperforms adjuvant regimens in resectable advanced Chinese melanoma patients: lymph node preservation as a key immunological advantage - Frontiers
Mon, 03 Jun 2024
Neoadjuvant Nivolumab-Ipilimumab Bests Adjuvant Nivolumab in Stage III Melanoma - Cancer Therapy Advisor
Sun, 02 Jun 2024
Neoadjuvant Nivolumab/Ipilimumab Emerges as SOC in Advanced Melanoma - Targeted Oncology
Fri, 21 Apr 2023
Linda Dunham Obituary - Houston, TX - Dignity Memorial
Mon, 20 Feb 2023
A nitric-oxide driven chemotactic nanomotor for enhanced immunotherapy of glioblastoma - Nature
Wed, 10 Mar 2021
Why Talend Stock Soared on Wednesday - The Motley Fool
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
